A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended
phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in
participants with non-Hodgkin lymphoma (NHL) relapsed and/or refractory after at least 1
prior line of therapy and to evaluate safety and tolerability of TAK-659 and venetoclax when
administered in combination.